The primary objective of this study was to evaluate the safety and tolerability of SG2918 in patients with relapsed/refractory multiple myeloma.
Age ≥ 18 years and ≤ 80 years.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
Life expectancy ≥ 3 months.
Documented diagnosis of multiple myeloma.
Patients with primary refractory multiple myeloma.
Presence of non-bone-related extramedullary soft tissue plasmacytoma at screening.
known meningeal or Central Nervous System involvement of multiple myeloma, or high suspicion of unconfirmed meningeal or Central Nervous System involvement.
History of peripheral neuropathy of Grade ≥ 2.